Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Fluorouracil + NLG207 + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 13||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|NLG207||IT-101|EP0057|CRLX101||NLG207 (CRLX101) is a nanoparticle conjugated to camptothecin, which inhibits topoisomerase-1 and HIF1-alpha, which may increase sensitivity to chemoradiation, and may result in tumor growth inhibition (PMID: 27784746, PMID: 33390325, PMID: 33632874).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|